

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 October 2020 (29.10.2020)



(10) International Publication Number
WO 2020/219743 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 25/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2020/029613

(22) International Filing Date:
23 April 2020 (23.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/838,093 24 April 2019 (24.04.2019) US
62/843,096 03 May 2019 (03.05.2019) US
62/858,495 07 June 2019 (07.06.2019) US

(71) Applicant: **VIELA BIO, INC.** [US/US]; One MedImmune Way, 5th Floor, Suite Area Two, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **KATZ, Eliezer**; c/o Viela Bio, Inc., One MedImmune Way, 5th Floor, Suite Area Two, Gaithersburg, Maryland 20878 (US). **DRAPPA, Jorn**; c/o Viela Bio, Inc., One MedImmune Way, 5th Floor, Suite Area

Two, Gaithersburg, Maryland 20878 (US). **MCKEEVER, Kathleen**; c/o Viela Bio, Inc., One MedImmune Way, 5th Floor, Suite Area Two, Gaithersburg, Maryland 20878 (US).

(74) Agent: **HOLMES-SON, Michelle** et al.; Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE




FIG. 1

(57) Abstract: Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular the use of VIB551, a humanised, affinity-optimised, afucosylated IgG1 kappa monoclonal antibody to treat Neuromyelitis optica spectrum disorder.

[Continued on next page]

WO 2020/219743 A3

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

10 December 2020 (10.12.2020)